PioneeringAdvanced TherapyMedicinalProducts (ATMPs)
The AES cleanroom has served as the critical environment to protect each of these first-of-its-kind immunotherapies that the United States FDA has approved to treat patients with debilitating diseases.
ThefirstFDA-approvedautologous celltherapywasapprovedin2010 forthetreatmentofmetastatic prostatecancers 2010
2017
SparkTherapeutics
ThefirstFDA-approvedgene therapyapprovedin2017for thetreatmentofinherited retinaldisease
ThefirstFDA-approvedCAR-Tcell therapyapprovedin2018forthe treatmentofacutelymphoblastic leukemia,largeB-celllymphoma, andfollicularlymphoma
2018 2024
Novartis/PENNMedicine IovanceBiotherapeutics
ThefirstFDA-approvedtumorinfiltratinglymphocyte(TIL)therapy approvedin2024forthetreatment ofadvancedmetastaticmelanoma DendreonCorporation
Each of these drugs leveraged a new modality that is helping to create and deliver new treatments, including ultimate cures AES has been at the forefront in the genesis of these technologies that have transformed medicine, and we are proud of our role in enabling this life-changing science to be pioneered inside of our facilities.
To learn more about AES Clean Technology and how it partners with trailblazing companies redefining lifesaving therapies, visit us at aesclean com
To
learn more about AES, scan here: